Can a smartphone app help kids with obesity stick to treatment?

NCT ID NCT06520787

Completed Symptom relief Sponsor: Adhera Health, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a digital health program (Adhera Caring Digital Program®) combined with standard medication for 40 families of children aged 13-18 with obesity. The goal was to see if the program improved treatment satisfaction, adherence, and mood over one year. Participants used a smartwatch, received personalized messages, and had monthly check-ins with health coaches.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adhera Caring Digital Program® (digital therapeutic software, personalized messages, educational materials) plus pharmacological treatment (orlistat, metformin, liraglutide, or semaglutide)
What this could lead to: If successful, this could show that combining a digital support program with medication helps families better manage childhood obesity, improving treatment satisfaction and adherence.
What could go wrong: This is a small feasibility study with only 40 families, so results may not apply to everyone. It focuses on short-term outcomes like satisfaction and mood, not long-term weight loss or health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY, CHILDHOOD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Pediatric Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY, CHILDHOOD

Contacts and locations

Locations

Hospital Universitario Miguel Servet

Zaragoza, Aragon, 50009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.